Option Notice Sample Clauses

Option Notice. VGS will provide Grantor written notice of its intent to exercise the option at any time after the Effective Date and on or before 11:59 p.m. (ET) on the last day of the Option Period (the “Option Notice”). The Option Notice must be delivered to Grantor’s mailing address and email account set forth on the payment direction form. Where requested by VGS, Grantor shall review and assist with a property questionnaire to prepare documents for the “Closing” as defined below.

Option Notice. 2 Section 1.03

Option Notice. The term “

Option Notice. Landlord shall institute the procedure described in this Article 18 by giving notice thereof (the “Option Notice”) to Tenant, which Option Notice shall (i) describe the Option Space (or the applicable portion thereof) (the Option Space (or such portion thereof) that is described in a particular Option Notice being referred to herein as the “Applicable Option Space”), (ii) have attached thereto a floor plan depicting the Applicable Option Space, (iii) set forth the date that Landlord reasonably expects that the Applicable Option Space will be vacant and available for Tenant’s occupancy (such date designated by Landlord being referred to herein as the “Scheduled Option Space Commencement Date”), and (iv) set forth Landlord’s calculation of the number of square feet of Rentable Area in the Applicable Option Space. The Scheduled Option Space Commencement Date shall not be (I) more than four hundred fifty (450) days, or (II) less than ninety (90) days, after the date that Landlord gives the Option Notice to Tenant; provided, however, if the Applicable Option Space shall be available for Tenant’s occupancy as a result of a default by the existing occupant of the Applicable Option Space and the involuntary termination of such occupant’s occupancy rights therefor, then the Scheduled Option Space Commencement Date shall be not less than thirty (30) days after the date that Landlord gives the Option Notice to Tenant.

Option Notice. On or prior to the Closing, the Company shall prepare and deliver, after providing to Parent an opportunity to comment and reasonably considering any comments from Parent, a notice to each Person holding a Company Option notifying such holder of a Company Option of the ability to exercise any such vested Company Option prior to the Effective Time and the treatment of such Company Option under Section 1.2(a)(iii) in the event that such Company Option remains unexercised and outstanding as of the Effective Time.

Option Notice. On a Licensed Product-by-Licensed Product basis, at least [*]prior to the anticipated date of Initiation of the first Pivotal Study for such Licensed Product (as such date of Initiation is set forth in the draft Cost Share Development Plan provided pursuant to this Section 6.2 or otherwise determined by the JSC, each an “Anticipated Pivotal Study Date”), Astellas shall provide to Sutro, to the extent not already in Sutro’s possession (a) all material clinical data to be included in the clinical study report (CSR) for all Clinical Trials conducted prior to initiation of the first Pivotal Study in the form then available, (b) all material preclinical data as well as all material data related to Development work conducted on such Licensed Product, (c) documentation of all substantive interactions with Regulatory Authorities as well as Regulatory Materials (e.g. the IND) for such Licensed Product, and (d) a U.S. development plan describing the overall plan for the Development of Licensed Compounds and Licensed Products in the United States, including all Clinical Trials intended to support Regulatory Approval from the FDA for such Licensed Product that would be Initiated following Sutro’s exercise of a Cost Share Option (if it were to do so), and related budget detailing the fully burdened cost for conducting such Clinical Trials and other Development activities (including for (i) Global Trials and (ii) global activities or activities outside the United States (other than Global Trials) that are reasonably allocable to Development in the United States), including a regulatory strategy for obtaining marketing approval from the FDA for the Licensed Product (each a “Cost Share Development Plan” and each corresponding budget, the “Cost Share Development Budget”). The Parties shall in good faith discuss such initial Cost Share Development Plan and Cost Share Development Budget through the JSC and the Parties shall discuss and, prior to the Option Effective Date, agree in writing (and outside the purview of JSC discussions) upon [*]. If the Parties cannot reach agreement on such FTE Rates, then the dispute shall be resolved in accordance with Section 15.4(c). Sutro may, in its sole discretion, exercise the Cost Share Option and, in connection with the exercise of such Cost Share Option, exercise the CoPro Option, for such Licensed Product, provided that in each case it must do so by notifying Astellas in writing of such option exercise at least [*]before the Anticip...

Option Notice. We refer to the Put Option Agreement dated as of [•] 2015 between LATAM Airlines Group S.A. and MaplesFS Limited (the "Put Option Agreement").

Option Notice. Legacy shall notify Primary immediately in writing upon (i) Ag Partner’s exercise of its Option under the Existing Ag Agreement to be granted exclusive rights to make, have made, use, sell, and import Viamet Derived Products incorporating any particular VDC or Derivatives thereof and (ii) the expiration of the Option Term with respect to any VDC, specifying in such notice the identity and structure of the VDC subject to such exercise or expiration and the date of any such exercise or expiration.

Option Notice. Verve has the right to deliver to the Escrow Agent, prior to the expiration of the Term, a Target Notice including the information set forth in Exhibit 4.2(c), as applicable, with respect to up to [**] Human Genome Target(s), the Genome Editing Protein Targets and Guide RNAs included in the Licensed Products for which Verve wishes to exercise an Option (each such Target Notice, an “Option Notice”). Each Option Notice will specify up to [**] Genome Editing Constructs (including the Genome Editing Protein Targets and Guide RNAs included therein) and up to [**] Human Genome Targets. Verve will submit one (1) Option Notice for each Licensed Product for which Verve wishes to exercise the Option and each Licensed Product will be defined by the Genome Editing Constructs and Human Genome Target(s) set forth in the Option Notice.